Table 7.

Probabilistic sensitivity analysis for HAPO (4) in a population with NICE risk factors

Diagnostic threshold	NMB* CE threshold £30 000 per QALY	Probability cost-effective CE threshold £20 000 per QALY (%)	Probability cost-effective CE threshold WTP=£30 000 per QALY (%)
No treatment	£0	54.1	21.0
NICE 2015	£239 902	43.3	51.5
WHO 2013	£186 675	2.7	27.6

*NMB is measured relative to a baseline of no treatment

CE, cost-effectiveness; HAPO, Hyperglycaemia and Adverse Pregnancy Outcomes; NICE, National Institute for Health and Care Excellence; NMB, net monetary benefit; QALY, quality-adjusted life year; WTP, willingness to pay.